Zacks Investment Research upgraded shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) from a sell rating to a hold rating in a report issued on Wednesday.

According to Zacks, “Intellia Therapeutics is a leading genome editing company, focused on developing therapeutics utilizing a biological tool known as CRISPR-Cas9 system. It believes the CRISPR-Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company’s sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. Intellia’s combination of deep scientific, technical and clinical development experience, along with its leading intellectual property portfolio, puts it in a unique position to unlock broad therapeutic applications of the CRISPR-Cas9 technology and create a new class of therapeutic products. “

NTLA has been the topic of several other reports. ValuEngine raised shares of Intellia Therapeutics from a sell rating to a hold rating in a report on Friday, September 22nd. Wedbush reaffirmed an ourperform rating and set a $25.00 price objective (down from $29.00) on shares of Intellia Therapeutics in a report on Wednesday, September 27th. Jefferies Group LLC reaffirmed a buy rating and set a $36.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, October 3rd. Cann reaffirmed a market perform rating on shares of Intellia Therapeutics in a report on Monday, July 17th. Finally, Barclays PLC initiated coverage on shares of Intellia Therapeutics in a report on Wednesday, September 6th. They set an overweight rating and a $29.00 price objective on the stock. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of Hold and a consensus target price of $26.80.

Intellia Therapeutics (NASDAQ:NTLA) opened at 30.93 on Wednesday. The company’s market capitalization is $1.12 billion. Intellia Therapeutics has a 52-week low of $10.83 and a 52-week high of $31.90. The company’s 50-day moving average is $24.93 and its 200-day moving average is $24.93.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.45) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.03). The business had revenue of $5.90 million for the quarter, compared to analysts’ expectations of $5.83 million. Intellia Therapeutics had a negative net margin of 204.48% and a negative return on equity of 22.70%. The firm’s revenue was up 40.5% compared to the same quarter last year. On average, analysts expect that Intellia Therapeutics will post ($1.78) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Intellia Therapeutics, Inc. (NTLA) Upgraded to “Hold” at Zacks Investment Research” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/10/08/intellia-therapeutics-inc-ntla-upgraded-to-hold-at-zacks-investment-research.html.

In other news, major shareholder Venture Fund Ix L.P. Atlas sold 150,000 shares of the company’s stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $16.24, for a total transaction of $2,436,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 12.80% of the company’s stock.

Several hedge funds have recently bought and sold shares of NTLA. SG Americas Securities LLC bought a new position in shares of Intellia Therapeutics in the second quarter worth approximately $101,000. IHT Wealth Management LLC bought a new position in shares of Intellia Therapeutics in the first quarter worth approximately $117,000. Bank of Montreal Can increased its position in shares of Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after purchasing an additional 7,222 shares during the last quarter. Nationwide Fund Advisors increased its position in shares of Intellia Therapeutics by 117.7% in the second quarter. Nationwide Fund Advisors now owns 8,048 shares of the company’s stock worth $129,000 after purchasing an additional 4,351 shares during the last quarter. Finally, Nisa Investment Advisors LLC bought a new position in shares of Intellia Therapeutics in the second quarter worth approximately $134,000. Institutional investors own 46.52% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Get a free copy of the Zacks research report on Intellia Therapeutics (NTLA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Stock Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related stocks with our FREE daily email newsletter.